$DMAC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.19 down -5.56% YoY • DiaMedica Therapeutics Inc. expects to incur substantial operating losses and negative cash flows, anticipated to moderately increase due to ongoing DM199 clinical development. Current cash resources are sufficient for planned operations for at least the next 12 months.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.